Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01547793 · ClinicalTrials.gov registry record
Carbon Monoxide Levels and Sickle Cell Disease Severity
A clinical trial, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- 106
- Enrollment target
NCT01547793: Completed study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT01547793 is a clinical trial that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 106 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01547793 has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- 106 participants
- Enrollment target
Study Summary
Background: \- Some people with sickle cell disease have different health problems than others. This may be related to how easily and frequently the red blood cells break apart in the blood. Researchers want to test breath and blood samples from people with sickle cell disease to look for very small amounts of carbon monoxide, which is produced when red blood cells break apart. They will compare these results with breath samples from healthy volunteers. Studying different levels of carbon monoxide may help predict what health problems a person with sickle cell disease may get. It may also provide more information on possible treatments. Objectives: \- To study breath carbon monoxide levels and their possible relation to the severity of sickle cell disease. Eligibility: * Individuals at least 18 years of age with sickle cell disease. * Healthy volunteers who are matched for age, sex, and race with the sickle cell disease group. Design: * Participants will be screened with a medical history. * Participants with sickle cell disease will provide a blood sample and have a heart function test. They will also breathe into a bag to provide an exhaled breath sample. * Healthy volunteers will provide an exhaled breath sample. * No treatment or care will be provided as part of this study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2012-01-26 |
| Est. Completion | 2015-11-04 |
What the finished NCT01547793 record still lists
NCT01547793 is an observational study that tracks outcomes without assigning an intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01547793 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01547793 about?
NCT01547793 is a clinical study titled "Carbon Monoxide Levels and Sickle Cell Disease Severity". Background: \- Some people with sickle cell disease have different health problems than others. This may be related to how easily and frequently the red blood cells break apart in the blood. Researchers want to test breath and blood samples from people with sickle cell disease to look for very smal...
What is the current status of trial NCT01547793?
This trial is currently completed. The enrollment target is 106 participants. The study started on 2012-01-26. Estimated completion is 2015-11-04.
Who is sponsoring clinical trial NCT01547793?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI